Incyte Corporation (INCY) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Incyte published the results on October 29, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. Incyte reports EPS two ways: GAAP, under the accounting rules every US filer follows, and Non-GAAP, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• Incyte recorded a one-time $1.23 billion in-process R&D expense for its acquisition of Vega Therapeutics in Q3 2026. Its non-GAAP measures do not exclude it, so both GAAP and non-GAAP EPS were losses.
• Because Incyte had a net loss, all stock options and awards were left out of the diluted share count, so diluted and basic EPS are the same for Q3 2026.

Source: Incyte Q3 2026 results, October 29, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Incyte splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Incyte's Total net sales revenue was $1.3 billion in Q3 2026, up 14% from $1.1 billion in Q3 2025, 85% of total revenue.
• Incyte's Total royalty revenues revenue was $191 million in Q3 2026, up 12% from $171 million in Q3 2025, 12% of total revenue.
• Incyte's Milestone and contract revenues revenue was $49.8 million in Q3 2026, up 11% from $45.0 million in Q3 2025, 3% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

In its Q3 2026 release, Incyte said:

“Incyte is raising its full year 2026 net sales guidance for Opzelura to $1,100-$1,120 million, Hematology and Oncology to $890-$910 million and total net sales to $5,210-$5,300 million to reflect continued strong performance across the portfolio.”

“Incyte is reaffirming its full year 2026 guidance for all other categories.”

“Includes upfront cost related to the acquisition of Vega Therapeutics, which was recognized as a $1.23 billion IPR&D expense in the third quarter of 2026.”

Source: Incyte Q3 2026 release, Oct 29, 2026.

This is the company's own guidance as of Oct 29, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the INCY forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP total revenues and diluted EPS, each as first reported in that quarter's release. Q2 2026 revenue includes a one-time $246.0 million Opzelura benefit from Incyte's agreement with CMS; Q3 2026 EPS includes the $1.23 billion Vega IPR&D expense.

We do not hold a confirmed date for Incyte's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Oct 29, 2026

Incyte's Q3 2026 revenue of $1,557.2 million came from three sources: net sales of its own drugs ($1,316.4 million), royalties on drugs it licenses to partners ($191.0 million) and milestone and contract revenues ($49.8 million). Jakafi, its ruxolitinib tablet for myelofibrosis, polycythemia vera and GVHD, was $826.5 million, about 63% of net sales. (Incyte Q3 2026 release, Oct 29, 2026)

Incyte said Jakafi net sales rose 4% to $827 million on a 12% increase in paid demand and growth across all indications, and that the figure now includes Jakafi XR, launched in Q2 2026. The 10-K says the patents covering ruxolitinib's composition of matter and use expire in mid and late 2028. In August Incyte agreed with CMS to let state Medicaid programs buy Jakafi at prices aligned with a group of other industrialized nations. (Incyte Q3 2026 release, Oct 29, 2026; Incyte Form 10-K, 2025, Feb 10, 2026)

Incyte's other products grew faster than Jakafi. Opzelura cream net sales rose 36% to $255 million, which Incyte put down to patient demand in atopic dermatitis and vitiligo and better net pricing after the Opzelura line extension settlement in Q2. Hematology and Oncology net sales rose 38% to $235 million on demand for Niktimvo ($67.4 million), Zynyz ($58.3 million) and Monjuvi/Minjuvi ($54.6 million). (Incyte Q3 2026 release, Oct 29, 2026)

Royalties come mainly from Novartis, which sells ruxolitinib outside the United States as Jakavi ($132.5 million in Q3 2026), and from Eli Lilly's Olumiant ($39.1 million). By geography, the United States accounted for $1,435.0 million of total revenues, Europe $107.4 million and other countries $14.9 million. (Incyte Q3 2026 release, Oct 29, 2026; Incyte Form 10-K, 2025, Feb 10, 2026; Incyte Form 10-Q, Q3 2026, Oct 29, 2026)

Incyte reported a GAAP diluted loss of $3.86 a share in Q3 2026, against EPS of $2.11 a year earlier, because of a one-time $1.23 billion IPR&D expense for the acquisition of Vega Therapeutics, which added the Phase 3 von Willebrand disease drug latarcibart. Non-GAAP diluted EPS was a loss of $3.60: Incyte's non-GAAP measures exclude stock-based compensation, amortization of acquired product rights, contingent consideration changes and equity investment gains and losses, but not the IPR&D charge. (Incyte Q3 2026 release, Oct 29, 2026)

Incyte recorded a tax provision of $96.0 million on a pre-tax loss of $688.8 million, an effective tax rate of (13.9)%, because the $1.23 billion charge is not deductible. Excluding the Vega expense, Incyte said GAAP operating income rose 18%. (Incyte Form 10-Q, Q3 2026, Oct 29, 2026; Incyte Q3 2026 release, Oct 29, 2026)

Shares used for Q3 2026 EPS were 203.2 million, against 201.4 million diluted a year earlier; the net loss meant no options or awards were added for dilution. Option holders exercised 3,404,545 shares in the first nine months of 2026, bringing in $295.4 million. (Incyte Q3 2026 release, Oct 29, 2026; Incyte Form 10-Q, Q3 2026, Oct 29, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Incyte gives full-year guidance in its release and raised it with Q3 2026: total net sales of $5,210 million to $5,300 million (previously $5,130 million to $5,260 million), Opzelura of $1,100 million to $1,120 million and Hematology and Oncology of $890 million to $910 million. Jakafi guidance of $3,220 million to $3,270 million was unchanged. (Incyte Q3 2026 release, Oct 29, 2026)

Incyte also kept its guidance for total GAAP R&D and SG&A expenses at $4,915 million to $4,995 million, which includes the Vega IPR&D expense, and non-GAAP R&D and SG&A at $4,625 million to $4,695 million. The Opzelura guidance includes a one-time $246 million benefit from the CMS Medicaid rebate settlement. (Incyte Q3 2026 release, Oct 29, 2026)

A consensus figure is the average of the models published by the analysts who cover Incyte, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Incyte's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning INCY is on is INCY a buy or a sell?, what analysts expect next is on the INCY forecast, and what the company does is on the Incyte Corporation (INCY) stock page.

Every number on this page can be traced to a document Incyte published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.